1 of 1
Story summary
- WuXi Biologics forecasts a 46.3% profit increase for 2025, expecting earnings of approximately 4.91 billion yuan (US$710 million).
- The company projects a 16.7% revenue rise to 21.79 billion yuan, attributing growth to its "follow and win the molecule" strategy.
- Shares increased by 3.2% to HK$41.32, reflecting a 31.4% year-to-date gain.
- WuXi Biologics added 209 new integrated projects in 2025, including 23 under its strategy, with six in Phase III trials.
- The company is located in Wuxi, Jiangsu province, eastern China.
